The ongoing judicial case challenging patents covering the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, held by the company Myriad Genetics, may thus have a significant effect on the course and implications of patenting for cffDNA testing if the validity of patents on genes or genetic diagnostic technologies is called into question [41]. Here, BRCA2 is linked to ovarian carcinoma.